Single Time Point Whole-Body Tumour Dosimetry as an Independent Prognostic Biomarker for Treatment Outcome in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Lutetium-177 [177Lu]Lu-PSMA-617

被引：0
|
作者：
Eifer, M. [1 ,2 ,3 ,4 ]
Papa, N. [1 ,2 ]
Kashyap, R. [1 ,2 ,5 ]
Buteau, J. P. [1 ,2 ,5 ]
McIntosh, L. [1 ,2 ]
Alipour, R. [1 ,2 ,5 ]
Azad, A. A. [5 ,6 ]
Akhurst, T. [1 ,2 ]
Cardin, A. [1 ,2 ,5 ]
Chen, D. [1 ,2 ]
Emmerson, B. [1 ,2 ]
Fettke, H. [5 ,7 ]
Haskali, M. [1 ,2 ,5 ]
Jewell, K. [1 ,2 ,5 ]
Kong, G. [1 ,2 ,5 ]
Kostos, L. [5 ,6 ]
Kumar, A. S. Ravi [1 ,2 ,5 ]
Macfarlane, L. [1 ,2 ]
Medhurst, E. [1 ,2 ,5 ]
Murphy, D. G. [5 ,8 ]
Saghebi, J. [1 ,2 ,5 ]
Sandhu, S. [5 ,6 ]
Tran, B. [5 ,6 ]
Jackson, P. [1 ,2 ,5 ]
Hofman, M. S. [1 ,2 ,5 ]
机构：
[1] Peter MacCallum Canc Ctr, Canc Imaging, Mol Imaging & Therapeut Nucl Med, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Prostate Canc Theranost & Imaging Ctr Excellence, Melbourne, Vic, Australia
[3] Chaim Sheba Med Ctr, Dept Diagnost Imaging, Ramat Gan, Israel
[4] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[5] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[6] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[7] Peter MacCallum Canc Ctr, Canc Res Div, Melbourne, Vic, Australia
[8] Peter MacCallum Canc Ctr, Div Canc Surg, Melbourne, Vic, Australia
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-578
引用
收藏
页码：S281 / S281
页数：1
相关论文
共 50 条
  • [31] The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (177Lu)-PSMA-617
    Yazgan, Sati Coskun
    Yekeduz, Emre
    Araz, Mine
    Bolek, Hatice
    Kucuk, N. Ozlem
    Urun, Yuksel
    PROSTATE, 2024,
  • [32] Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
    Sun, Michael
    Niaz, Muhammad O.
    Nelson, Adlai
    Skafida, Myrto
    Niaz, Muhammad J.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (06)
  • [33] Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
    Violet, John
    Jackson, Price
    Ferdinandus, Justin
    Sandhu, Shahneen
    Akhurst, Tim
    Iravani, Amir
    Kong, Grace
    Kumar, Aravind Ravi
    Thang, Sue Ping
    Eu, Peter
    Scalzo, Mark
    Murphy, Declan
    Williams, Scott
    Hicks, Rodney J.
    Hofman, Michael S.
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (04) : 517 - 523
  • [34] Multi- cycle dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study
    Kurth, J.
    Rahbar, K.
    Eiber, M.
    Sparks, R.
    Baca, N.
    Krause, B. J.
    Lassmann, M.
    Jentzen, W.
    Chicco, D.
    Klein, P.
    Blumenstein, L.
    Basque, J.
    Herrmann, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S129 - S129
  • [35] Comment on, 177Lu-PSMA-617 in metastatic, castration-resistant prostate cancer"
    Radtke, Jan Philipp
    Albers, Peter
    Giesel, Frederik Lars
    AKTUELLE UROLOGIE, 2022, 53 (02)
  • [36] Overview of selected completed prospective studies on PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer
    Karimzadeh, Amir
    Lehnert, Wencke
    Koehler, Daniel
    Shenas, Farzad
    Kisters, Anna
    Apostolova, Ivayla
    Klutmann, Susanne
    Adam, Gerhard
    Sauer, Markus
    ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN, 2025,
  • [37] Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
    Gadot, Moran
    Davidson, Tima
    Aharon, Margalit
    Atenafu, Eshetu G.
    Malki, Avraham
    Levartovsky, Meital
    Saad, Akram
    Domachevsky, Liran
    Berger, Raanan
    Leibowitz, Raya
    CANCERS, 2020, 12 (05)
  • [38] [177Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study
    Satapathy, Swayamjeet
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Sahoo, Ranjit Kumar
    Bal, Chandrasekhar
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 (08) : 2495 - 2503
  • [39] Building a predictive model for outcomes with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results
    Herrmann, Ken
    Gafita, Andrei
    De Bono, Johann S.
    Sartor, A. Oliver
    Chi, Kim N.
    Krause, Bernd J.
    Rahbar, Kambiz
    Tagawa, Scott T.
    Czernin, Johannes
    El-Haddad, Ghassan
    Wong, Connie
    Zhang, Zhaojie
    Wilke, Celine
    Mirante, Osvaldo
    Morris, Michael J.
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: A substudy of the VISION trial
    Kurth, Jens
    Herrmann, Ken
    Eiber, Matthias
    Rahbar, Kambiz
    Heuschkel, Martin
    Lassmann, Michael
    Jentzen, Walter
    Chicco, Daniela
    Messmann, Richard
    Sartor, A. Oliver
    Morris, Michael J.
    Krause, Bernd J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345